Drugs / IBENTATUG
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05074472 | Jan 2022 → Aug 2023 | biliary tract cancer, ovarian serous cystadenocarcinoma, pancreatic ductal adenocarcinoma | ZielBio, Inc. | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IBENTATUG | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314839 ↗ |
| Known as | ZB131 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05074472 ↗ |
| Modality | Monoclonal antibody | — CHEMBL5314839 ↗ |
| Route | Intravenous | “ZB131 will be administered once weekly by intravenous infusion” NCT05074472 ↗ |